Watchlist Price Alert

Sutro Biopharma Inc. (STRO)

NASDAQ: STRO · Real-Time Price · USD

0.78

-0.04 (-4.31%)

At close: May 13, 2025, 3:59 PM

-4.31% (1D)

Bid	0.57
Market Cap	65.49M
Revenue (ttm)	62.04M
Net Income (ttm)	-227.46M
EPS (ttm)	-2.92
PE Ratio (ttm)	-0.27
Forward PE	-0.85
Analyst	Buy

Ask	0.98
Volume	154,970
Avg. Volume (20D)	1,924,146
Open	0.82
Previous Close	0.82
Day's Range	0.78 - 0.83
52-Week Range	0.52 - 5.17
Beta	1.78

About STRO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol STRO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for STRO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Sutro Biopharma has released their quartely earnings on May 8, 2025:

Revenue of $17.4M exceeds estimates by $8.4M, with 33.76% YoY growth.

EPS of -0.91 exceeds estimates by 0.01, with 4.21% YoY growth.

Why Price Moved

2 months ago

-35.19%

Sutro Biopharma shares are trading lower after B o... Unlock content with Pro Subscription

6 months ago

-12.88%

Sutro Biopharma shares are trading lower after the company reported worse-than-expected Q3 sales results.

News

5 days ago · zacks.com

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago.

2 months ago · benzinga.com

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.

2 months ago · zacks.com

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago.